Loading...
Market
What will be the market share of Vorasidenib among IDH-mutant glioma treatments by end of 2024?
2
Resolution / Starting Odds
0-10% • 25%
11-20% • 25%
21-30% • 25%
Over 30% • 25%
Market analysis reports from reputable sources
Story
FDA Approves Servier's Vorasidenib for Low-Grade Glioma
Aug 7, 2024, 12:28 AM
The U.S. Food and Drug Administration (FDA) has approved Servier's vorasidenib, branded as Voranigo, for the treatment of low-grade glioma, a type of brain cancer. The drug, originally developed by Agios Pharmaceuticals (AGIO) as AG-881, targets IDH-mutant glioma in patients aged 12 and older. Data from the phase 3 INDIGO trial demonstrated that vorasidenib significantly improved progression-free survival (PFS), with a median PFS of 27.7 months compared to 11.1 months for placebo, resulting in a 61% risk reduction. This approval marks a significant milestone for Servier, following its acquisition of the drug, and applies to two types of rare brain cancer.
View original story
Similar markets
Ivonescimab > Keytruda • 25%
Ivonescimab = Keytruda • 25%
Ivonescimab < Keytruda • 25%
Neither has significant market share • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
0-10% • 25%
10-20% • 25%
20-30% • 25%
30% or more • 25%
Below 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
Above 60% • 25%
Less than 10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
More than 50% • 25%
Less than 20% • 25%
20%-40% • 25%
40%-60% • 25%
More than 60% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%